MedTrace Logo

Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation

NCT02379676 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2016-07-06

No results posted yet for this study

Summary

The purpose of this study is to compare the effects of ticagrelor and clopidogrel on endothelial dysfunction and vascular inflammation

Ticagrelor will lead to beneficial pleiotropic effects compared with treatment with clopidogrel in patients receiving a drug-eluting stents (DES) during percutaneous coronary intervention (PCI) for non-ST-segment acute coronary syndrome (NSTE-ACS) beyond 1 month after the index event. Ticagrelor treatment will improve percent flow-mediated dilation (FMD) values and reduces inflammatory gene expression on peripheral blood mononuclear cells.

Conditions

  • Endothelial Dysfunction
  • Vascular Inflammation

Interventions

DRUG

Ticagrelor

Ticagrelor 90mg twice daily for 30 days

DRUG

Clopidogrel

Clopidogrel 75mg once daily for 30 days

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Kiyuk Chang

    lead OTHER

Principal Investigators

  • Kiyuk Chang, MD, PhD · Seoul St. Mary's Hospital, The Catholic.University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-12-31
Completion
2017-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02379676 on ClinicalTrials.gov